ReviewCancer gene therapy2012
A review of RGD-functionalized nonviral gene delivery vectors for cancer therapy.
Review in Cancer gene therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 97 citations in OpenAlex.
- Dual-Targeted M1 Macrophage Extracellular Vesicles Reprogram the Tumor Microenvironment and Enhance Natural Killer Cell Immunotherapy in Breast Cancer.Journal of extracellular vesicles · 2026Article
- RGD-based self-assembling nanodrugs for improved tumor therapy.Frontiers in pharmacology · 2024Review
- Synthesis of Novel Carborane-Containing Derivatives of RGD Peptide.Molecules (Basel, Switzerland) · 2023Article
- Structure-Activity Relationships of RGD-Containing Peptides in Integrin αvβ5-Mediated Cell Adhesion.ACS omega · 2023Article
- Molecular ZIP codes in targeted drug delivery.Proceedings of the National Academy of Sciences of the United States of America · 2022Review
- Design and Synthesis of Porphyrin-Nitrilotriacetic Acid Dyads with Potential Applications in Peptide Labeling through Metallochelate Coupling.ACS omega · 2022Article
- Review
- Recent Advances in Preclinical Research Using PAMAM Dendrimers for Cancer Gene Therapy.International journal of molecular sciences · 2021Review
- Endothelial Cell Targeting by cRGD-Functionalized Polymeric Nanoparticles under Static and Flow Conditions.Nanomaterials (Basel, Switzerland) · 2020Article
- Biomimetic Nanotechnology toward Personalized Vaccines.Advanced materials (Deerfield Beach, Fla.) · 2020Review
- Antimetastatic Potential of Rhodomyrtone on Human Chondrosarcoma SW1353 Cells.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Biodegradable Polymers for Gene Delivery.Molecules (Basel, Switzerland) · 2019Review
- Mixed Peptide-Conjugated Chitosan Matrices as Multi-Receptor Targeted Cell-Adhesive Scaffolds.International journal of molecular sciences · 2018Review
- Nonviral Gene Therapy for Cancer: A Review.Diseases (Basel, Switzerland) · 2018Review
- Double domain polyethylenimine-based nanoparticles for integrin receptor mediated delivery of plasmid DNA.Scientific reports · 2018Article
- Molecular design of upconversion nanoparticles for gene delivery.Chemical science · 2017Review
- Article
- Engineering liposomal nanoparticles for targeted gene therapy.Gene therapy · 2017Review
- Cancer-Associated, Stimuli-Driven, Turn on Theranostics for Multimodality Imaging and Therapy.Advanced materials (Deerfield Beach, Fla.) · 2017Review
- Apoptin Gene Delivery by the Functionalized Polyamidoamine (PAMAM) Dendrimer Modified with Ornithine Induces Cell Death of HepG2 Cells.Polymers · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of effective treatments that enable many patients suffering from cancer to be successfully cured is highly demanded. Angiogenesis, which is a process for the formation of new capillary blood vessels, has a crucial role in solid tumor progression and the development of metastasis. Antiangiogenic therapy designed to prevent tumor angiogenesis, thereby arresting the growth or spread of tumors, has emerged as a non-invasive and safe option for cancer treatment. Due to the fact that integrin receptors are overexpressed on the surface of angiogenic endothelial cells, various strategies have been made to develop targeted delivery systems for cancer gene therapy utilizing integrin-targeting peptides with an exposed arginine-glycine-aspartate (RGD) sequence. The aim of this review is to summarize the progress and prospect of RGD-functionalized nonviral vectors toward targeted delivery of genetic materials in order to achieve an efficient therapeutic outcome for cancer gene therapy, including antiangiogenic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.